| HOME >> BIOLOGY >> TECHNOLOGY |
COS Consultants Evaluate Purification Testing, Standards and Procedures
SHAANXI, China, July 29 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and raw materials used in the production of pharmaceuticals, nutraceuticals and food production, today released an investor update on the status of its application for COS approval for the delivery of Diosmin to Safic-Alcan.
COS, or European Certification of Suitability, approval is required before Huifeng can begin shipments of Diosmin to the European Community. As previously announced, Huifeng estimates COS approval in September.
In order to assure compliance with the application process, Huifeng recently retained and was visited by a certified COS approval consulting firm. The consultants performed a thorough, on-site inspection of Huifeng's Diosmin production facilities, including an evaluation of the purification testing, procedures and standards. In addition, the consultants provided the company with guidance pertaining to the COS application filing process.
"Huifeng is taking all necessary steps to keep pace with the established timeline for the COS application filing and approval process," stated Jing'An Wang, CEO/President of Huifeng. "Our COS consultants have not only assisted us in this process, but gave us very high marks regarding our Diosmin preparation and compliance with the COS standards."
COS certification is the final stage of approval for Huifeng to begin
shipments of Diosmin to French company Safic-Alcan under a supply agreement
announced last November. The supply agreement between Huifeng and
Safic-Alcan grants Safic-Alcan exclusive rights to market Diosmin in the
European market. The agreement also sets forth minimum guaranteed
quantities to be delivered over each of the five years of the contract. The
minimum quantity of Diosmin to be delivered in year on
'/>"/>
| SOURCE Huifeng Bio-Pharmaceutical Technology, Inc. Copyright©2008 PR Newswire. All rights reserved |